Dinardo, C. D., Stein, E., Pigneux, A., Altman, J. K., Collins, R., Erba, H. P., … de Botton, S. (2020). Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Dinardo, Courtney Denton, Eytan Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry Paul Erba, Justin M. Watts, et al. “Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Dinardo CD, Stein E, Pigneux A, Altman JK, Collins R, Erba HP, et al. Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Dinardo, Courtney Denton, et al. “Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Dinardo CD, Stein E, Pigneux A, Altman JK, Collins R, Erba HP, Watts JM, Uy GL, Kapsalis SM, Liu H, Winkler T, Roboz GJ, de Botton S. Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML). JOURNAL OF CLINICAL ONCOLOGY. 2020.